Treatment
Participants were randomized to one of the following oral, single-dose combination therapies: ivermectin 200 μg/kg plus albendazole 400 mg (IA), given annually (standard of care for LF MDA in Cote d’Ivoire), moxidectin 8 mg plus albendazole 400 mg (MoxA), ivermectin 200 μg/kg plus DEC 6 mg/kg plus albendazole 400 mg (IDA), or moxidectin 8 mg plus DEC 6 mg/kg plus albendazole 400 mg (MoxDA). Study medications were prepared and administered by an unblinded pharmacist, according to a pre-designated block randomization list. No other personnel had access to the randomization or to which arm participants were randomized. Participants and all individuals performing laboratory tests, assessing TEAE, performing physical or ultrasound exams were blinded to study arm.